Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report

BACKGROUND: Pulmonary sarcomatoid carcinoma (PSC) is a rare and unconventional non-small-cell lung cancer (NSCLC) that appears to be aggressive, with a poor prognosis and response to conventional treatment. Approximately 30% of PSCs have potentially targetable genomic alterations, but few studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Ying, Yan, Zhecheng, Pan, Juan, Chang, Xiaona, Huang, Bo, Luo, Danju, Meng, Rui, Shi, Heshui, Fan, Jun, Nie, Xiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724403/
https://www.ncbi.nlm.nih.gov/pubmed/36471407
http://dx.doi.org/10.1186/s12957-022-02848-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724403/
https://www.ncbi.nlm.nih.gov/pubmed/36471407
http://dx.doi.org/10.1186/s12957-022-02848-z

Ejemplares similares